Repurposing Paroxetine: Inhibiting MET and ERBB3 in Human Colon Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, with high rates of metastasis and limited effectiveness of current therapies. While traditional chemotherapeutics like 5-fluorouracil and targeted agents (e.g., cetuximab, bevacizumab) have improved outcomes, resistance and modest benefit persist as significant challenges. In recent years, drug repositioning—identifying new therapeutic uses for existing drugs—has gained traction as a strategy to accelerate the development of effective oncology treatments. Among various non-oncological agents, antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have shown intriguing anticancer properties in preliminary studies. However, the molecular mechanisms underlying these effects remain incompletely understood. The reference study (Jang et al., 2019) addresses whether paroxetine, a well-characterized SSRI, exerts direct anticancer activity against human colon cancer cells and elucidates its mechanistic targets.

Key Innovation from the Reference Study

The central innovation of this research lies in uncovering that paroxetine suppresses colorectal cancer cell growth through a mechanism involving inhibition of the receptor tyrosine kinases MET and ERBB3. This expands the pharmacological profile of paroxetine—traditionally known as a selective serotonin reuptake inhibitor—by positioning it as a dual MET and ERBB3 kinase inhibitor in the context of colon cancer. These kinases are key drivers of proliferative and survival signaling in many tumor types, and their inhibition represents a targeted approach to cancer therapy. The study notably provides in vitro and in vivo evidence, supporting the concept of drug repositioning and offering a new therapeutic angle for CRC treatment.

Methods and Experimental Design Insights

The authors employed a multi-tiered experimental design to evaluate both cellular and molecular outcomes of paroxetine treatment in CRC models:

• Human colorectal cancer cell lines (HCT116 and HT-29) were treated with increasing concentrations of paroxetine.
• Cell viability was assessed using MTT assays, while colony formation and 3D spheroid formation assays evaluated long-term proliferative and anchorage-independent growth potential.
• Apoptosis was quantified via flow cytometry and caspase-3 activation.
• Western blot analysis investigated phosphorylation and activation status of MET, ERBB3, and downstream signaling effectors (AKT, ERK, p38, JNK, caspase-3).
• In vivo efficacy was tested in athymic nude mice xenografted with HT-29 cells, measuring tumor growth following paroxetine administration.

This integrative design allowed the authors to link phenotypic effects (reduced proliferation, increased apoptosis) with specific molecular changes in kinase signaling pathways.

Protocol Parameters

• Cell line treatment: Paroxetine concentrations typically ranged from 7 to 26 μM for in vitro assays, matching the range where significant anti-proliferative and pro-apoptotic effects were observed according to the reference study.
• Colony and spheroid assays: Cells were cultured for 10–14 days (colony) and 5–7 days (spheroid) post-treatment to assess sustained effects on growth.
• Xenograft model dosing: Mice received paroxetine intraperitoneally; dosing regimens should be referenced directly from the study or adapted based on pilot tolerability in local animal protocols.
• Apoptosis assessment: Caspase-3 activation and annexin V/PI staining were key readouts for apoptotic induction.

Core Findings and Why They Matter

The major findings from the study can be summarized as follows:

• Paroxetine reduces CRC cell viability and proliferation: Both HCT116 and HT-29 cells exhibited dose-dependent loss of viability and colony formation in response to paroxetine.
• Induction of apoptosis: Treated cells showed a marked increase in apoptotic markers, including caspase-3 cleavage and JNK pathway activation.
• Suppression of MET and ERBB3 phosphorylation: Paroxetine treatment significantly inhibited phosphorylation of MET and ERBB3, with downstream reduction in AKT, ERK, and p38 MAPK activation—key pathways promoting cell survival and proliferation.
• Inhibition of 3D spheroid formation: The compound disrupted the ability of colon cancer cells to form multicellular tumor spheroids, a feature associated with metastatic potential.
• In vivo tumor growth suppression: In mouse xenograft models, paroxetine administration led to a significant reduction in HT-29 tumor growth, corroborating the in vitro findings.

The identification of paroxetine as a MET and ERBB3 inhibitor is particularly significant because these kinases are validated targets in metastatic CRC, and resistance to current targeted therapies is often driven by reactivation of these pathways. By mechanistically linking paroxetine’s anticancer effects to kinase inhibition, the study provides a rationale for further preclinical and clinical exploration of this SSRI in oncology.

Comparison with Existing Internal Articles

Recent reviews such as "Paroxetine Mesylate: Multi-Target Pharmacology and Research Impact" and "Paroxetine: Molecular Mechanisms Beyond Serotonin Reuptake Inhibition" have outlined the broad spectrum of paroxetine’s molecular interactions. These include its high affinity for the serotonin transporter (SERT), notable inhibition of cytochrome P450 enzymes (especially CYP2D6), and emerging roles as a kinase inhibitor. The reference study by Jang et al. directly confirms and extends these mechanistic insights by showing functional inhibition of receptor tyrosine kinases MET and ERBB3 in CRC models. As previously described in "Paroxetine: Multi-Target Mechanisms and Molecular Insights", the multi-target profile of paroxetine supports its translational potential in both neuropsychiatric and oncology research. The current study provides the first in vivo evidence that these multi-target activities translate to tangible antitumor effects in CRC, further validating the relevance of kinase inhibition as a research endpoint for paroxetine derivatives.

Limitations and Transferability

Despite its promising findings, the study has several limitations:

• Cell line specificity: Only two human CRC cell lines were tested; broader applicability across CRC subtypes remains to be established.
• In vivo model constraints: The xenograft model uses immunocompromised mice, which do not fully recapitulate the tumor microenvironment or immune interactions present in patients.
• Dose translation: The concentrations effective in vitro and in xenograft models may not directly correspond to clinically achievable plasma levels in humans, raising questions about translational dosing and safety.
• Mechanistic scope: While MET and ERBB3 inhibition is clearly implicated, paroxetine’s known activities as a cytochrome P450 inhibitor (notably CYP2D6) and G protein-coupled receptor kinase 2 (GRK2) inhibitor were not directly addressed in this study, but may contribute to broader pharmacodynamic effects.

Thus, while the data are compelling for preclinical exploration, further studies in diverse models and with clinical pharmacokinetic correlation are warranted before considering translation to patient use.

Why this cross-domain matters, maturity, and limitations

The repositioning of paroxetine from a psychiatric SSRI to an anticancer agent exemplifies the value of cross-domain drug discovery, leveraging established safety and pharmacology data to accelerate oncology research. However, maturity is currently limited to preclinical models; no clinical trials have yet evaluated paroxetine or its mesylate salt as a MET or ERBB3 inhibitor in CRC patients. Transferability to other cancer types or combinatorial regimens remains speculative without direct evidence.

Research Support Resources

For researchers seeking to investigate the multi-target pharmacology and anticancer potential of SSRIs, Paroxetine Mesylate (SKU C8698) from APExBIO is available for in vitro and in vivo studies. This compound (Paroxetine mesylate CAS 217797-14-3) is characterized by high affinity for SERT and documented kinase inhibition, supporting reproducibility in workflows similar to those described in the reference study. Standard storage at -20°C is recommended to preserve stability. For protocol troubleshooting and advanced application tips, the article "Paroxetine Mesylate: Applied SSRI Research & Troubleshooting Guide" may be helpful.